FY2024 Earnings Estimate for OKUR Issued By Leerink Partnrs

OnKure Therapeutics (NASDAQ:OKUR) – Equities researchers at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for shares of OnKure Therapeutics in a research note issued to investors on Thursday, December 5th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($3.89) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ Q4 2024 earnings at ($1.10) EPS, FY2025 earnings at ($4.31) EPS, FY2026 earnings at ($3.19) EPS, FY2027 earnings at ($3.91) EPS and FY2028 earnings at ($3.65) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Thursday, November 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.13).

A number of other equities analysts have also recently commented on OKUR. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of OnKure Therapeutics in a report on Friday, November 8th. Lifesci Capital raised OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Oppenheimer assumed coverage on shares of OnKure Therapeutics in a research report on Thursday, October 10th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Leerink Partners assumed coverage on shares of OnKure Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $33.00 price target for the company. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, OnKure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $36.00.

OnKure Therapeutics Stock Down 0.3 %

Shares of NASDAQ OKUR opened at $14.16 on Monday. The firm has a market capitalization of $47.29 million, a PE ratio of -1.16 and a beta of 0.14. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $77.60. The company’s 50 day moving average is $16.77.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.